A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma
- Robert Marcus
- , R. Aultman*
- , F. Jost
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
14
Citations
(Scopus)